10:24 AM EDT, 10/17/2024 (MT Newswires) -- Avadel Pharmaceuticals ( AVDL ) said Thursday the US Food and Drug Administration approved its supplemental new drug application for Lumryz to treat cataplexy, or excessive daytime sleepiness, in narcolepsy patients aged seven and older.

The FDA also granted Lumryz Orphan Drug exclusivity in pediatric narcolepsy patients 7 years and older until Oct. 16, 2031, the company said.

Avadel shares were 2% higher in recent trading.

Price: 13.52, Change: +0.28, Percent Change: +2.11